Tirzepatide Medicinal

Tirzepatide Muscle Loss: Lean-Mass Research

Before the details

Tirzepatide muscle loss is real: when the drug produces large weight reductions, not all of the weight lost is fat. Roughly one-quarter is lean mass — which includes muscle. This matters because muscle does more than lift things: it is metabolically active tissue that affects strength, balance, resting energy expenditure, and long-term metabolic health. The good news is that most of the weight lost is fat (about three-quarters), and the loss of lean mass appears to track the same proportion seen with other weight-loss approaches including dietary restriction and older bariatric therapies. The clinical question — whether this lean-mass loss causes meaningful loss of strength and function over time — is still being studied. What is known: resistance exercise training appears to significantly offset lean-mass loss during incretin therapy. This page summarises what the trials measured.

The SURMOUNT-1 DXA substudy: fat versus lean at 72 weeks

The most detailed body-composition data on tirzepatide comes from a post hoc DXA (dual-energy X-ray absorptiometry — an imaging method that separates fat, lean, and bone mass) substudy of SURMOUNT-1 (Look M, et al., Diabetes Obes Metab 2025; n=160; pooled tirzepatide n=124, placebo n=36) [11].

From baseline to week 72, changes in body weight, fat mass, and lean mass were:

  • Tirzepatide: body weight -21.3%, fat mass -33.9%, lean mass -10.9%
  • Placebo: body weight -5.3%, fat mass -8.2%, lean mass -2.6%

Of the total weight lost, approximately 75% was fat mass and approximately 25% was lean mass with tirzepatide — proportions that were consistent across most subgroup analyses including by sex, age, BMI category, and the presence or absence of prediabetes at baseline [11].

The proportional fat/lean split is similar to what has been documented with lifestyle-only weight loss and with older bariatric procedures, suggesting it reflects a general biological pattern of weight loss rather than a tirzepatide-specific effect. Whether larger absolute lean-mass losses — as happen with very large total weight reductions — carry greater functional consequences is an active area of investigation.

What the systematic review found: skeletal muscle

A 2025 systematic review (Cureus; PMID 40895971) characterised changes in skeletal muscle mass during tirzepatide-induced weight loss across multiple study designs [5]. The review confirmed that skeletal muscle loss occurs alongside fat loss, consistent with the SURMOUNT-1 DXA substudy, and noted that the available studies differ in how they measure lean mass (DXA, bioelectrical impedance, appendicular lean mass) — which makes cross-study comparisons imprecise. Few studies have measured objective physical function (grip strength, gait speed, chair stands) alongside body composition, leaving the functional significance of lean-mass loss incompletely characterised.

A 2025 narrative review in Annals of Internal Medicine (Batsis JA, et al.; PMID 41996180) further examined the effect of incretin-based weight loss on lean mass across multiple agents, reinforcing that lean-mass loss of roughly 25–30% of total weight lost appears consistent across the incretin drug class [25].

The resistance exercise data: preserving muscle during tirzepatide

A narrative review in Diabetes Care (Locatelli JC, et al., 2024; PMID 38687506) synthesised the case for resistance exercise training as a protective strategy during incretin-based weight loss [12]. Key findings:

  • Supervised resistance exercise training lasting more than ten weeks can produce approximately 3 kg lean mass gains and approximately 25% improvements in strength.
  • The authors recommend resistance exercise as an adjunct to incretin therapy for people concerned about lean-mass preservation.
  • Neither tirzepatide nor any other incretin agonist has been studied in a randomised trial specifically designed to test exercise as a lean-mass-protective intervention.

A 2026 phase 2 randomised controlled trial (EMBRAZE; Pratley RE, et al., Nat Med 2026; PMID 42260100; n=102) tested apitegromab — a myostatin-activation inhibitor (myostatin is a protein that limits muscle growth) — added to tirzepatide. At 24 weeks, apitegromab produced 1.9 kg less lean mass loss than placebo (P=0.001), representing 54.9% lean mass retention relative to placebo, without reducing total body weight loss [32]. This is the most direct evidence yet that lean-mass loss during tirzepatide therapy can be pharmacologically mitigated, though apitegromab is not approved and this is early-phase data.

The context for tirzepatide muscle loss remains: real, proportionally similar to other major weight-loss interventions, and incompletely characterised for functional impact — with resistance exercise as the best-evidenced available adjunct.

Fat distribution: visceral and liver fat

Body weight is a blunt instrument. The SURPASS-3 MRI substudy (Gastaldelli A, et al., Lancet Diabetes Endocrinol 2022; n=296) illuminated where tirzepatide's fat loss comes from in people with type 2 diabetes, comparing tirzepatide 10/15 mg with insulin degludec [8].

Absolute liver fat content reduction: -8.09 percentage points with tirzepatide versus -3.38 with insulin degludec (treatment difference -4.71%; P<0.0001). Visceral adipose tissue volume was also significantly reduced.

A complementary analysis (Cariou B, et al., Diabetes Obes Metab 2024) compared tirzepatide-treated participants with sex- and BMI-matched virtual controls from the UK Biobank imaging cohort [9]. At baseline, participants had elevated visceral and liver fat relative to population norms but similar subcutaneous fat. Tirzepatide significantly decreased visceral fat (z-VAT -0.18; P<0.001) and liver fat (z-LF -0.54; P<0.001) while subcutaneous fat moved toward population norms — a shift in body-fat distribution pattern that could not be predicted from body-weight change alone [9].

The practical implication: a meaningful share of tirzepatide's metabolic benefit may derive specifically from the preferential reduction of visceral and ectopic fat, which are the fractions most strongly linked to insulin resistance, dyslipidaemia, and cardiovascular risk.